Related Experiment Video
Updated: May 8, 2026
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Pertuzumab for the treatment of metastatic breast cancer
Simon P Langdon1, David A Cameron
1Division of Pathology, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XU, UK. simon.langdon@ed.ac.uk
Abstract:
Approximately 15% of primary breast cancers have amplification/overexpression of the cell surface receptor HER2. Despite the major improvements in survival achieved by the use of adjuvant trastuzumab, many of these patients still develop metastatic disease, and other patients with HER2 overexpressing breast cancer have overt metastases at first diagnosis. There remains therefore a pressing medical need to identify better therapies for these patients. Pertuzumab is a humanized antibody that targets and binds HER2. Although only modestly active against breast cancer when used as a single agent, pertuzumab has demonstrated significant activity when combined with trastuzumab against trastuzumab-resistant and -sensitive disease. Multiple clinical trials are underway to define the optimal use of pertuzumab (combined with either trastuzumab or trastuzumab-DM1) together with a range of cytotoxic agents or endocrine therapy in multiple settings of HER2-overexpressing breast cancer. This article summarizes the use of pertuzumab in the metastatic disease setting.
Insights
Pertuzumab, combined with trastuzumab, shows significant activity against HER2-positive metastatic breast cancer. This combination offers a promising therapeutic option for patients with both trastuzumab-resistant and -sensitive disease.
Area of Science:
- Oncology
- Pharmacology
Background:
- Approximately 15% of primary breast cancers exhibit HER2 amplification/overexpression.
- Despite trastuzumab improvements, many HER2-positive breast cancer patients develop metastatic disease, necessitating novel therapies.
Purpose of the Study:
- To summarize the therapeutic applications of pertuzumab in the context of HER2-overexpressing metastatic breast cancer.
- To highlight the efficacy of pertuzumab in combination regimens for HER2-positive breast cancer.
Main Methods:
- Review of clinical trials and therapeutic data concerning pertuzumab in metastatic breast cancer.
- Analysis of pertuzumab's activity as a single agent and in combination with trastuzumab.
Main Results:
- Pertuzumab, a humanized antibody targeting HER2, demonstrates significant activity when combined with trastuzumab.
- The combination of pertuzumab and trastuzumab is effective in both trastuzumab-resistant and -sensitive HER2-overexpressing breast cancer.
Conclusions:
- Pertuzumab, in combination with trastuzumab, represents a key advancement in treating HER2-positive metastatic breast cancer.
- Ongoing clinical trials are exploring optimal combinations of pertuzumab with other agents for various treatment settings.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
02:56Treatment Resistant Cancers